GPCR / Should You Still Buy the Nasdaq's Best-Performing October Stocks?

Structure Therapeutics' weight-loss drug candidate is attracting attention over excitement about obesity treatments. ImmunityBio rallied on hopes that more_horizontal

Structure Therapeutics (GPCR) rises 9% on encouraging initial data from the early-stage study of its pipeline candidate, GSBR-1290, in healthy overwei more_horizontal

Structure Therapeutics' oral small molecule GLP-1, GSBR-1290, has shown promising results in Phase 1b studies, surpassing competitor benchmarks for we more_horizontal

Analysts upgraded their price targets for Structure Therapeutics. The company's obesity therapy can be taken as a once-daily pill. more_horizontal

Structure Therapeutics Inc shares surged 34% to $50.34 in midday trading on Friday after the clinical-stage global biopharmaceutical company announced more_horizontal

Structure's weight-loss drug candidate is of the same class as Mounjaro and Wegovy, but while those drugs must be injected, Structure's is taken orall more_horizontal

Structure's pill is part of the same class of drugs as Novo Nordisk's blockbuster diabetes drug Ozempic and weight loss counterpart Wegovy. more_horizontal

Shares of Structure Therapeutics soared 60% on Friday after the drug developer's oral obesity treatment succeeded in a small early-stage study. more_horizontal